Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024

Core Insights - Sanara MedTech Inc. expects a net revenue increase of 45% to 48% year-over-year for Q4 2024 and a full-year increase of 32% to 33% [1][5] Financial Performance - Q4 2024 net revenue is projected to be between $25.7 million and$26.2 million, driven by strong sales of soft tissue repair products, particularly CellerateRX Surgical Activated Collagen and BIASURGE [5] - Full-year net revenue for 2024 is anticipated to be in the range of $86.0 million to$86.5 million [5] - As of December 31, 2024, the company had approximately $15.9 million in cash,$30.5 million in principal debt obligations, and $24.5 million in available borrowing capacity [5] Operational Highlights - The company achieved its thirteenth consecutive record net revenue quarter, with significant sales attributed to BIASURGE due to supply chain issues caused by Hurricane Helene [4][5] - Sanara submitted 11 provisional patent applications in 2024 related to innovations in proprietary antimicrobial technologies and hydrolyzed collagen [4][5] Leadership Changes - On October 4, 2024, Mr. Keith Myers was appointed to the Board of Directors, bringing extensive experience from his role as chairman and CEO emeritus of LHC Group [5]